Specialisation
Glaucoma.
Full title
Phase III: Assessment of the efficacy and safety of a fixed combination of unpreserved latanoprost drops and timolol 0.5% (T2347) versus Xalacom® in patients with ocular hypertension or glaucoma.
Promoter
Théa
Start date
March 2015
End date
May 2016
Researchers
Principal: Dr Elena Arrondo
